Medisafe 1 Technologies Retains Robinson Medical Marketing Consultants

JERUSALEM, November 3, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has retained Robinson Medical Marketing Services Ltd., as marketing and distribution consultants.

Robinson Medical (http://www.robinson-medical.com/) is an international marketing specialist with over 30 years of experience in international marketing of top tier medical products. Robinson Medical represents leading Israeli health-care product manufacturers, acting as a third-party marketing division by opening new distributional channels and providing with comprehensive export management.

"We believe that there is a large market for Medisafe's patented locking syringe," said Jacob Elhadad, Chief Executive Officer of Medisafe 1 Technologies. "Retaining Robinson Medical offers us the increased capability to locate importers, distributors, and sales representatives, and close agreements with relevant partners."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

    Contact:
    JACOB ELHADAD
    CEO
    +972-524440000
    [email protected]

SOURCE Medisafe 1 Technologies Corp.